Fewer than half of Americans own a passport. Some say that’s because their own backyard is such a big one. The half of our audience that hails from there may not be aware of what’s happening with global travel because they’re blissfully watching the stock market soar inexplicably. According to the World Tourism Barometer, international […]
One can’t help but wonder why the Americans are so worried about peanut allergies when 34 million of them use a product every day that slowly kills them. In the United States, cigarette smoking is linked to about 80% to 90% of lung cancer deaths. While we may not be able to pry someone’s cigarettes from their […]
We don’t usually do this sort of stuff, but we’d like to start this article off letting everyone know about an exciting SPAC opportunity. John from Cameroon – a region in the great country of Africa – emailed us about a pre-revenue cosmetics/wood timber/software development outsourcing company that’s looking for a SPAC to have an […]
Drug discovery is one of the keystone themes we cover on Nanalyze, and we’re not just talking about finding new cannabis dispensaries in the smoking Pacific Northwest. Creating novel medicines from scratch to treat disease isn’t cheap. A study published this year calculated it costs an average of $1.3 billion to develop a new drug […]
Wasn’t even 48 hours ago that we were commenting on how one of Illumina’s big venture bets – Grail – didn’t seem to be doing much. And here we are today, poring over their S-1 filing as the Illumina-backed venture has just filed for an Initial Public Offering (IPO). Since we’re long Guardant (GH) given […]
The so-called “cure for cancer” isn’t one magical treatment that may or may not be secretly hidden from everyone as part of a vast conspiracy by big pharma. Today’s spray-and-pray approach to cancer treatment has varying degrees of success targeting the over 200 types of cancer, each instance of which is unique to the patient. […]
This year we learned about a mind-blowing advance in brain-computer interface (BCI) technology for recording and interpreting neural signals. Founded by a wealthy and outsized personality, the West Coast startup has raised more than $100 million to advance the boundaries of neuroscience, augment human memory, and perhaps meld mind and machine in mind-bending ways. You […]
This past spring we wrote about “The Only Telehealth Stock for Telemedicine Investors,” an article with a misleading title. That’s because there soon may be two pure-play stocks to consider in this space. In that article, we noted that none of the other major players in telehealth are publicly traded, but “that could change now […]
Saint Steve Jobs once said that the biggest innovations of the twenty-first century will be at the intersection of biology and technology. Look no further than next-generation sequencing (NGS) which now lets us read DNA, and artificial intelligence algorithms that help us understand DNA. If we think of a DNA strand as a 1.5-gigabyte chunk of computer […]
We recently did a deep dive into the available robotic surgery stocks on the market. The article only considered pure-play companies where a significant portion of their revenues are derived from that particular emerging technology. Otherwise, you may end up with a list of great companies, such as Johnson & Johnson (JNJ), but get little […]